Actively Recruiting
Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
Led by Instituto Nacional de Cancerologia de Mexico · Updated on 2025-03-26
33
Participants Needed
1
Research Sites
188 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.
CONDITIONS
Official Title
Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of epithelial ovarian cancer (all subtypes) at stage III or IV
- Partial or complete response after 3-4 cycles of neoadjuvant chemotherapy, confirmed by PET-CT imaging
- CA 125 blood level less than 200
- ECOG performance status 0 to 2 without medical contraindications for surgery (ASA score 64 2 or Goldman score 64 2)
You will not qualify if you...
- Partial response with ongoing ascites or pleural effusion
- Presence of unresectable disease including multiple intrahepatic liver metastases
- Retroperitoneal lymph node clusters larger than 2 cm above the renal lymph nodes
- Metastatic disease above the diaphragm
- Multiple intestinal involvements and mesentery retraction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Instituto Nacional de Cancerologia
México, Tlalpan, Mexico, 14080
Actively Recruiting
Research Team
D
David Isla Ortiz, MD, M. Cs.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here